Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$3.47
-$0.05(-2.07%)
At close: 4:00 PM EST
$3.47
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous CloseN/A
Volume369.36K
Average Volume (3M)746.47K
Market Cap
$162.41M
Enterprise Value$1.26
Total Cash (Recent Filing)$230.43M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume693,723
30 Day Avg. Volume746,470
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.80Price Target Upside240.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic NK PlatformNkarta's off-the-shelf allogeneic NK cell approach is a durable business-model advantage: it targets scalable, centralized manufacturing and broader patient access versus autologous therapies. Over 2–6 months this structural model supports lower per-patient production complexity and potential faster commercial ramp if clinical success is achieved.
Moderate LeverageA moderate debt-to-equity ratio indicates the company is not overly reliant on interest-bearing debt, preserving financial flexibility. Over the medium term this reduces default risk and supports the ability to raise non-debt capital for R&D, making the balance sheet a relative strength amid persistent operating losses.
Governance AlignmentRecent shareholder approvals, board elections and auditor ratification strengthen governance and shareholder oversight. Annual say-on-pay adoption and refreshed directors can improve accountability, governance continuity, and credibility with investors and potential partners over the medium term, aiding strategic execution and future financings.
Bears Say
High Cash BurnPersistent negative operating and free cash flow (roughly -$87M to -$88M TTM) implies continued reliance on external financing. Over 2–6 months this structural cash burn elevates dilution and refinancing risk, potentially constraining R&D cadence or forcing unfavorable capital raises if clinical timelines slip.
Pre-revenue StatusAs a pre-commercial biotech with no reported revenue, long-term value depends entirely on clinical and regulatory success. This lack of product revenue limits visibility into sustainable earnings or margins and makes the company vulnerable to trial setbacks or longer development timelines over the next several months.
Eroding Equity BaseDeclining shareholder equity and persistently negative returns indicate that capital is being consumed rather than compounded. Structurally this erodes the firm’s cushion against adverse outcomes and increases likelihood of future dilutive financings, weakening investor capital protection over the medium term.
Nkarta News
NKTX FAQ
What was Nkarta, Inc.’s price range in the past 12 months?
Nkarta, Inc. lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta, Inc.’s market cap?
Nkarta, Inc.’s market cap is $162.41M.
When is Nkarta, Inc.’s upcoming earnings report date?
Nkarta, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Nkarta, Inc.’s earnings last quarter?
Nkarta, Inc. released its earnings results on May 12, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.016.
Is Nkarta, Inc. overvalued?
According to Wall Street analysts Nkarta, Inc.’s price is currently Undervalued.
Does Nkarta, Inc. pay dividends?
Nkarta, Inc. does not currently pay dividends.
What is Nkarta, Inc.’s EPS estimate?
Nkarta, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Nkarta, Inc. have?
Nkarta, Inc. has 71,545,360 shares outstanding.
What happened to Nkarta, Inc.’s price movement after its last earnings report?
Nkarta, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -6.707%.
Which hedge fund is a major shareholder of Nkarta, Inc.?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (240.06% Upside)
$11.80 (240.06% Upside)
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.94%
Trailing 12-Months
Company Description
Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(240.06% Upside)
Technical Analysis
Ownership Overview
20.64% Insiders
7.77% Mutual Funds
2.38% Other Institutional Investors
62.16% Public Companies and
Individual Investors